PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
文献类型：期刊论文
| 作者 | Wei, Qing1,2; Yuan, Xing1,2; Li, Jingjing1,2; Xu, Qi1,2; Ying, Jieer1,2 |
| 刊名 | TRANSLATIONAL CANCER RESEARCH
 |
| 出版日期 | 2020-09-01 |
| 卷号 | 9 |
| 关键词 | Programmed death 1 (PD-1) gastric cancer (GC) immune checkpoint inhibitors immunotherapy apatinib |
| ISSN号 | 2218-676X |
| DOI | 10.21037/tcr-20-1333 |
| 通讯作者 | Xu, Qi(hzxuqi@sina.cn) ; Ying, Jieer(jieerying@aliyun.com) |
| 英文摘要 | Background: Nivolumab and pembrolizumab were approved as immune checkpoint inhibitors for third-line treatment of advanced gastric or esophagogastric junction cancer (GC/EGJC) in 2017. However, immunotherapy monotherapy has low efficacy. Apatinib has been proven effective in advanced GC/EGJC. Numerous studies have shown that immunotherapy has a synergistic effect when combined with targeted drug therapy. Based on these facts and to assess the efficacy and safety of programmed death 1 (PD-1) inhibitor and apatinib as combination therapy in patients (pts) with unresectable locally advanced or metastatic GC/EGJC, a retrospective clinical research study was carried out. Methods: Pts (n=24) received PD-1 inhibitor and apatinib (250 mg once daily) as second- or third-line therapy in this observational, retrospective study. The primary objectives were efficacy and safety. Results: At data cut-off (December 31, 2019), 24 pts were enrolled. Of the 19 pts who were evaluable, the objective response rate (ORR) was 26.3% (5/19), the median progression-free survival (PFS) was 3.0 (95% CI: 1.3 to 4.7) months, and the median overall survival (OS) was not reached. Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 3 (15.8%) of the 19 pts. These adverse events (AEs) included pruritus, rash, hand-foot syndrome, and increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT). No treatment-related deaths occurred. Conclusions: Combination therapy of PD-1 inhibitor and apatinib showed encouraging clinical activity and demonstrated tolerable toxicity in pts with advanced GC/EGJC. Hence, our work provide rationale for the combination of PD-1 inhibitor and apatinib in advanced GC/EGJC. |
| WOS关键词 | TUMOR MICROENVIRONMENT ; DOUBLE-BLIND ; IMMUNOTHERAPY ; CHEMOTHERAPY ; VASCULATURE ; THERAPIES ; BLOCKADE |
| 资助项目 | Zhejiang Chinese Medicine Science and Technology Program[2018ZB022] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000575123400020 |
| 出版者 | AME PUBL CO |
| 资助机构 | Zhejiang Chinese Medicine Science and Technology Program |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/104299]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Xu, Qi; Ying, Jieer |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Abdominal Med Oncol, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wei, Qing,Yuan, Xing,Li, Jingjing,et al. PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study[J]. TRANSLATIONAL CANCER RESEARCH,2020,9. |
| APA | Wei, Qing,Yuan, Xing,Li, Jingjing,Xu, Qi,&Ying, Jieer.(2020).PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study.TRANSLATIONAL CANCER RESEARCH,9. |
| MLA | Wei, Qing,et al."PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study".TRANSLATIONAL CANCER RESEARCH 9(2020). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。